Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for CytomX Therapeutics (CTMX) over the last 10 years, with Q4 2023 value amounting to $73.8 million.

  • CytomX Therapeutics' Shares Outstanding (Weighted Average) rose 1227.32% to $73.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $73.8 million, marking a year-over-year increase of 1227.32%. This contributed to the annual value of $73.8 million for FY2023, which is 1227.32% up from last year.
  • Per CytomX Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $73.8 million for Q4 2023, which was up 1227.32% from $80.7 million recorded in Q3 2023.
  • In the past 5 years, CytomX Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $80.7 million in Q3 2023 and a low of $45.1 million during Q1 2019
  • Its 5-year average for Shares Outstanding (Weighted Average) is $58.6 million, with a median of $65.1 million in 2021.
  • Per our database at Business Quant, CytomX Therapeutics' Shares Outstanding (Weighted Average) soared by 4125.09% in 2021 and then surged by 67.97% in 2022.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Shares Outstanding (Weighted Average) stood at $45.3 million in 2019, then increased by 2.79% to $46.6 million in 2020, then soared by 40.12% to $65.3 million in 2021, then rose by 0.68% to $65.7 million in 2022, then grew by 12.27% to $73.8 million in 2023.
  • Its Shares Outstanding (Weighted Average) stands at $73.8 million for Q4 2023, versus $80.7 million for Q3 2023 and $66.5 million for Q2 2023.